ProKidney (PROK) Stock Forecast, Price Target & Predictions
PROK Stock Forecast
ProKidney stock forecast is as follows: an average price target of $4.00 (represents a 164.90% upside from PROK’s last price of $1.51) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
PROK Price Target
The average price target for ProKidney (PROK) is $4.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $3.00. This represents a potential 164.90% upside from PROK's last price of $1.51.
PROK Analyst Ratings
According to 7 Wall Street analysts, ProKidney's rating consensus is 'Buy'. The analyst rating breakdown for PROK stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ProKidney Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 04, 2024 | Jason Gerberry | Bank of America Securities | $3.00 | $2.40 | 25.00% | 98.68% |
| Sep 03, 2024 | Justin Zelin | BTIG | $5.00 | $2.40 | 108.33% | 231.13% |
| Jun 10, 2024 | Kelly Shi | Jefferies | $6.00 | $3.02 | 98.68% | 297.35% |
| May 28, 2024 | Justin Zelin | BTIG | $6.00 | $3.71 | 61.73% | 297.35% |
| Dec 21, 2022 | Jefferies | $15.00 | $7.30 | 105.48% | 893.38% |
The latest ProKidney stock forecast, released on Sep 04, 2024 by Jason Gerberry from Bank of America Securities, set a price target of $3.00, which represents a 25.00% increase from the stock price at the time of the forecast ($2.40), and a 98.68% increase from PROK last price ($1.51).
ProKidney Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $5.00 |
| Last Closing Price | $1.51 | $1.51 | $1.51 |
| Upside/Downside | -100.00% | -100.00% | 231.13% |
In the current month, the average price target of ProKidney stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ProKidney's last price of $1.51. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 10, 2024 | Guggenheim | Buy | Initialise | |
| Sep 03, 2024 | BTIG | Buy | Buy | Hold |
| Jun 10, 2024 | Jefferies | Buy | Buy | Hold |
| May 29, 2024 | Bank of America Securities | Neutral | Neutral | Hold |
| May 28, 2024 | BTIG | Buy | Buy | Hold |
| Dec 21, 2022 | Jefferies | Buy | Initialise | |
| Oct 14, 2022 | Citigroup | Buy | Initialise | |
| Sep 02, 2022 | Wells Fargo | Overweight | Initialise | |
| Sep 02, 2022 | Evercore ISI | Outperform | Initialise |
ProKidney's last stock rating was published by Guggenheim on Sep 10, 2024. The company Initialise its PROK rating from "null" to "Buy".
ProKidney Financial Forecast
ProKidney Revenue Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| # Analysts | - | - | - | - |
| Surprise % | - | - | - | - |
ProKidney's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PROK's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
ProKidney EBITDA Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EBITDA | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
undefined analysts predict PROK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ProKidney's previous annual EBITDA (undefined) of $NaN.
ProKidney Net Income Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| Net Income | - | - | - | - |
| Avg Forecast | $-21.45M | $-18.69M | $-16.10M | $-19.20M |
| High Forecast | $-21.45M | $-16.20M | $-16.10M | $-19.20M |
| Low Forecast | $-21.45M | $-18.69M | $-16.10M | $-19.20M |
| Surprise % | - | - | - | - |
ProKidney's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PROK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ProKidney SG&A Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| SG&A | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
ProKidney's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PROK last annual SG&A of $NaN (undefined).
ProKidney EPS Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EPS | - | - | - | - |
| Avg Forecast | $-0.17 | $-0.15 | $-0.13 | $-0.25 |
| High Forecast | $-0.17 | $-0.13 | $-0.13 | $-0.25 |
| Low Forecast | $-0.17 | $-0.15 | $-0.13 | $-0.25 |
| Surprise % | - | - | - | - |
According to undefined Wall Street analysts, ProKidney's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PROK previous annual EPS of $NaN (undefined).
ProKidney Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.37 | $33.86 | 1328.69% | Buy |
| BDTX | Black Diamond Therapeutics | $2.50 | $20.00 | 700.00% | Buy |
| RLAY | Relay Therapeutics | $4.50 | $18.00 | 300.00% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| ARVN | Arvinas | $19.10 | $58.50 | 206.28% | Buy |
| PLRX | Pliant Therapeutics | $14.37 | $35.50 | 147.04% | Buy |
| KURA | Kura Oncology | $9.74 | $23.33 | 139.53% | Buy |
| IMCR | Immunocore | $29.40 | $70.20 | 138.78% | Buy |
| ERAS | Erasca | $2.63 | $6.00 | 128.14% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| PROK | ProKidney | $1.85 | $4.00 | 116.22% | Buy |
| MRUS | Merus | $44.90 | $81.25 | 80.96% | Buy |
| THRD | Third Harmonic Bio | $11.35 | $20.00 | 76.21% | Buy |
| PCVX | Vaxcyte | $89.86 | $148.80 | 65.59% | Buy |
| REPL | Replimune Group | $11.72 | $19.00 | 62.12% | Buy |
| LYEL | Lyell Immunopharma | $0.65 | $1.00 | 53.85% | Hold |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| RVMD | Revolution Medicines | $45.16 | $65.67 | 45.42% | Buy |
| PTGX | Protagonist Therapeutics | $40.69 | $57.33 | 40.89% | Buy |
| ACLX | Arcellx | $82.03 | $111.60 | 36.05% | Buy |